Stanford Type A Aortic Dissection Can Be Treated with Endoprosthesis

Original title: Endovascular Repair of Ascending Aortic Dissection. A Novel Treatment Option for Patients Judged Unfit for Direct Surgical Repair. Reference: Qingsheng Lu, et al. J Am Coll Cardiol 2013;61:1917–24.

The dissecting aneurysm Type A represents 60% or aortic dissections and a real challenge as regards both therapeutics and the adequate moment to perform it, due to the serious complications this pathology entails. This analysis included 41 patients admitted between 2009 and 2011 with aortic dissection type A; all of them received endovascular treatment due to high surgical risk. Exclusion criteria included:

No patient presented death or any other complication at hospital level, except for two that presented arrhythmias. Hospital stay was 3.3±1 days. Follow up was 26 months (16-35); intervention was repeated in one case only; no patient presented severe aortic insufficiency or death. Complete thrombosis of ascending aorta false lumen was noted in all 15 patients and descending aorta false lumen thrombosis was seen in 10 patients. There were no changes in ejection fraction or in left ventricle end-diastolic diameter; a significant reduction of proximal and distal aorta diameter was observed, and a significant increase in true lumen.

Conclusion: 

The endovascular treatment of the Ascending Aorta Type A was the appropriate option for patients considered poor candidates for conventional surgery.

Commentary: 

Being able to solve this pathology by endoprosthesis implantation, with good outcomes, encourages us to use this strategy in patients that are no candidates for surgery. An analysis made by Dr. Sobocinski in the year 2011 had concluded that half of patients could be treated with this technique, which invites us to investigate further and motivates us to develop new, more efficient devices, to cover a larger number of patients. 

Courtesy of Dr. Carlos Fava
Interventional cardiologist.
Favaloro Foundation Argentina.

Dr. Carlos Fava.

More articles by this author

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Duration of Smoking Cessation and Risk of Amputation After Revascularization in Critical Limb Ischemia

Critical limb ischemia (CLI) is associated with high rates of amputation and mortality. Although smoking cessation improves outcomes after revascularization, the impact of the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...